Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway. NJPS [Internet]. 2025(e)ko abenduaren 31(e)an [aipatua 2026(e)ko apirilaren 14(e)an];40(2):251-62. Available at: https://www.ojshostng.com/index.php/njphysiologicalsciences/article/view/4001